Ñî¹óåú´«Ã½Ò•îl

People diagnosed with cancer during the first 2 years of the COVID-19 pandemic had worse short-term survival compared with cases in the years leading up to the pandemic, including for breast, prostate, colorectal, and other cancers, a population-based cohort study suggested. (Bassett, 2/5)

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. (Bassett, 2/10)

Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen (PSMA) PET/CT, a retrospective study with long-term follow-up showed. (Bankhead, 2/9)

An observational study from China finds that menstrual blood can be used to screen for HPV, the human papillomavirus, which causes 90% of all cervical cancer. Authors of the study hope their results could provide women with a less invasive, more convenient way to be screened for cervical cancer, which is expected to kill 4,200 US women this year. (Szabo, 2/5)

A common medication for diabetes may slow down age-related vision loss, according to new research. People with diabetes who were over the age of 55 and taking metformin — a prescription drug most commonly used to treat type 2 diabetes — were 37% less likely to develop intermediate age-related macular degeneration (AMD) over five years compared to those not taking it. (Quill, 2/10)